Literature DB >> 25962452

[Prognosis and therapy of inflammatory rheumatic diseases : Impact of renal manifestations].

M Zänker1, C D Cohen, H D Rupprecht.   

Abstract

BACKGROUND: Inflammatory rheumatic diseases and their treatment cause various renal manifestations requiring modification of treatment.
OBJECTIVES: Discussion of renal manifestations in selected rheumatic diseases, including their impact on general prognosis and therapy.
MATERIALS AND METHODS: Basic literature and expert opinions are analyzed and discussed.
RESULTS: Inflammatory rheumatic diseases and their treatment cause various renal manifestations, including glomerular, tubular, interstitial, and vascular damage. The type of damage determines both, associated clinical symptoms (i.e. hematuria, proteinuria, loss of kidney function) and the renal and overall survival as will be discussed here for rheumatoid arthritis, systemic lupus erythematosus, scleroderma, Sjögrens syndrome, cryoglobulinemia and ANCA-associated vasculitis.
CONCLUSION: Renal manifestations are generally indicators of high disease activity and usually require more intensive treatment of the underlying rheumatic disease. Early and rigorous treatment, which has to be adapted to renal function, is capable of improving renal and overall survival in many of the affected patients.

Entities:  

Mesh:

Year:  2015        PMID: 25962452     DOI: 10.1007/s00393-014-1479-8

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  60 in total

1.  Q: Should target natriuretic peptide levels be used for outpatient management of chronic heart failure?

Authors:  Ahmed Ibrahim; Motaz Baibars; M Chadi Alraies; Guilherme H Oliveira
Journal:  Cleve Clin J Med       Date:  2012-01       Impact factor: 2.321

2.  Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study.

Authors:  Jasper J Brugts; Annemarieke M Knetsch; Francesco U S Mattace-Raso; Albert Hofman; Jacqueline C M Witteman
Journal:  Arch Intern Med       Date:  2005 Dec 12-26

Review 3.  Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports.

Authors:  E S Strobel; E Fritschka
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

Review 4.  Treatment of hepatitis C: a systematic review.

Authors:  Anita Kohli; Ashton Shaffer; Amy Sherman; Shyam Kottilil
Journal:  JAMA       Date:  2014-08-13       Impact factor: 56.272

5.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.

Authors:  Loïc Guillevin; Christian Pagnoux; Alexandre Karras; Chahera Khouatra; Olivier Aumaître; Pascal Cohen; François Maurier; Olivier Decaux; Jacques Ninet; Pierre Gobert; Thomas Quémeneur; Claire Blanchard-Delaunay; Pascal Godmer; Xavier Puéchal; Pierre-Louis Carron; Pierre-Yves Hatron; Nicolas Limal; Mohamed Hamidou; Maize Ducret; Eric Daugas; Thomas Papo; Bernard Bonnotte; Alfred Mahr; Philippe Ravaud; Luc Mouthon
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

6.  Perinuclear antineutrophil cytoplasmic antibody in rheumatoid arthritis: a marker of severe disease with associated nephropathy.

Authors:  A Mustila; M Korpela; J Mustonen; H Helin; H Huhtala; E Soppi; A Pasternack; A Miettinen
Journal:  Arthritis Rheum       Date:  1997-04

7.  Long-term outcomes of scleroderma renal crisis.

Authors:  V D Steen; T A Medsger
Journal:  Ann Intern Med       Date:  2000-10-17       Impact factor: 25.391

8.  Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear.

Authors:  Michael Walsh; Alina Casian; Oliver Flossmann; Kerstin Westman; Peter Höglund; Charles Pusey; David R W Jayne
Journal:  Kidney Int       Date:  2013-04-24       Impact factor: 10.612

9.  Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker.

Authors:  Sang-Hoon Lee; Eun Jung Lee; Sang Wan Chung; Ran Song; Joo-Young Moon; Sang-Ho Lee; Sung-Jig Lim; Yeon-Ah Lee; Seung-Jae Hong; Hyung-In Yang
Journal:  Rheumatol Int       Date:  2012-12-27       Impact factor: 2.631

10.  Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis.

Authors:  Anoek A E de Joode; Jan Stephan F Sanders; Coen A Stegeman
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-11       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.